文献速递白血病淋巴瘤

SHP2是BCR-ABL1诱导血液系统肿瘤所必需的

SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
PubMed 文献 · Leukemia · 2017-08-14

该研究利用遗传功能缺失方法和骨髓移植模型,在慢性髓性白血病(CML)样骨髓增殖性肿瘤和BCR-ABL1阳性B细胞急性淋巴细胞白血病(B-ALL)模型中证明SHP2是BCR-ABL1诱发髓系和淋系肿瘤所必需的,并揭示SHP2通过SRC家族激酶和ERK抑制MXD3/4以促进MYC依赖性增殖程序。

要点

  • Ptpn11缺失损害CML样骨髓增殖性肿瘤的起始和维持,并影响BCR-ABL1阳性B-ALL的诱导。
  • SHP2的SH2结构域、PTP活性和C端酪氨酸对BCR-ABL1阳性前B细胞增殖必需,对野生型前B细胞非必需。
  • SHP2仅在BCR-ABL1阳性前B细胞中参与SRC家族激酶激活,MEK/ERK通路仅对BCR-ABL1阳性细胞增殖必需。

核心结论

  • SHP2是BCR-ABL1诱发髓系和淋系肿瘤所必需的,其通过SRC家族激酶和ERK抑制MXD3/4以促进BCR-ABL1转化前B细胞的MYC依赖性增殖程序。

研究设计与样本

  • 采用遗传功能缺失方法和骨髓移植模型研究CML和BCR-ABL1阳性B-ALL。

主要发现

  • Ptpn11缺失损害CML样骨髓增殖性肿瘤的起始和维持,并影响BCR-ABL1阳性B-ALL的诱导。
  • SHP2的SH2结构域、PTP活性和C端酪氨酸对BCR-ABL1阳性前B细胞增殖必需,对野生型前B细胞非必需。
  • MEK/ERK通路在野生型和BCR-ABL1阳性前B细胞中均受SHP2调控,但仅对BCR-ABL1阳性细胞增殖必需。
  • SHP2仅在BCR-ABL1阳性前B细胞中参与SRC家族激酶激活。
  • RNAseq显示BCR-ABL1阳性与野生型前B细胞中SHP2依赖性转录程序不同。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BCR-ABL1-targeting tyrosine kinase inhibitors (TKIs) have revolutionized treatment of Philadelphia chromosome-positive (Ph+) hematologic neoplasms. Nevertheless, acquired TKI resistance remains a major problem in chronic myeloid leukemia (CML), and TKIs are less effective against Ph+ B-cell acute lymphoblastic leukemia (B-ALL). GAB2, a scaffolding adaptor that binds and activates SHP2, is essential for leukemogenesis by BCR-ABL1, and a GAB2 mutant lacking SHP2 binding cannot mediate leukemogenesis. Using a genetic loss-of-function approach and bone marrow transplantation models for CML and BCR-ABL1+ B-ALL, we show that SHP2 is required for BCR-ABL1-evoked myeloid and lymphoid neoplasia. Ptpn11 deletion impairs initiation and maintenance of CML-like myeloproliferative neoplasm, and compromises induction of BCR-ABL1+ B-ALL. SHP2, and specifically, its SH2 domains, PTP activity and C-terminal tyrosines, are essential for BCR-ABL1+, but not WT, pre-B-cell proliferation. The mitogen-activated protein kinase kinase (MEK) / extracellular signal-regulated kinase (ERK) pathway is regulated by SHP2 in WT and BCR-ABL1+ pre-B cells, but is only required for the proliferation of BCR-ABL1+ cells. SHP2 is required for SRC family kinase (SFK) activation only in BCR-ABL1+ pre-B cells. RNAseq reveals distinct SHP2-dependent transcriptional programs in BCR-ABL1+ and WT pre-B cells. Our results suggest that SHP2, via SFKs and ERK, represses MXD3/4 to facilitate a MYC-dependent proliferation program in BCR-ABL1-transformed pre-B cells.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gu S, Sayad A, Chan G, et al. SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia. 2017. PMID: 28804122. doi:10.1038/leu.2017.250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。